The Journal of asthma : official journal of the Association for the Care of Asthma · 2026
"Translational models for acute asthma: critical evaluation of in vivo, in vitro, and emerging technologies in drug discovery".
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
A Raihana Nilofar, Priyadharsini Rajendran
Аннотация
OBJECTIVES: To critically evaluate conventional and emerging preclinical methodologies for screening novel asthma therapeutics; to compare their translational relevance; and to propose an integrated framework aimed at improving precision, safety, and phenotype-targeted efficacy in drug development.
DATA SOURCES: A review of peer-reviewed literature was conducted using PubMed. Sources included studies on enzymatic and receptor-binding assays, in vitro cellular platforms, allergen-induced animal models, and recent innovations such as 3D airway organoids, lung-on-a-chip microfluidics, and omics-guided biomarker discovery.
STUDY SELECTIONS: Included studies focused on (i) molecular validation of drug targets, (ii) mechanistic and high-throughput screening in cellular systems, (iii) in vivo replication of asthma pathophysiology in animal models, or (iv) technologies enhancing preclinical predictability.
RESULTS: Conventional screening assays provide molecular validation but lack complexity. In vitro systems allow mechanistic insight and scalability, yet do not fully reproduce airway interactions. Allergen-induced animal models replicate inflammation and hyperresponsiveness but fail to capture human heterogeneity or acute exacerbations, a major contributor to morbidity and mortality. Acute asthma remains particularly difficult to model, limiting evaluation of therapies aimed at severe attacks. Emerging approaches, including organoids, lung-on-a-chip, and omics-based biomarkers, offer improved physiological relevance, dynamic assessment of inflammatory responses, and greater potential to model acute disease states.
CONCLUSIONS: Integrating conventional and innovative models may accelerate the development of safer, more effective, and phenotype-specific asthma therapies. Approaches that incorporate both chronic disease and acute exacerbations could reduce steroid resistance, improve emergency care, and enhance translational success across diverse populations.
DATA SOURCES: A review of peer-reviewed literature was conducted using PubMed. Sources included studies on enzymatic and receptor-binding assays, in vitro cellular platforms, allergen-induced animal models, and recent innovations such as 3D airway organoids, lung-on-a-chip microfluidics, and omics-guided biomarker discovery.
STUDY SELECTIONS: Included studies focused on (i) molecular validation of drug targets, (ii) mechanistic and high-throughput screening in cellular systems, (iii) in vivo replication of asthma pathophysiology in animal models, or (iv) technologies enhancing preclinical predictability.
RESULTS: Conventional screening assays provide molecular validation but lack complexity. In vitro systems allow mechanistic insight and scalability, yet do not fully reproduce airway interactions. Allergen-induced animal models replicate inflammation and hyperresponsiveness but fail to capture human heterogeneity or acute exacerbations, a major contributor to morbidity and mortality. Acute asthma remains particularly difficult to model, limiting evaluation of therapies aimed at severe attacks. Emerging approaches, including organoids, lung-on-a-chip, and omics-based biomarkers, offer improved physiological relevance, dynamic assessment of inflammatory responses, and greater potential to model acute disease states.
CONCLUSIONS: Integrating conventional and innovative models may accelerate the development of safer, more effective, and phenotype-specific asthma therapies. Approaches that incorporate both chronic disease and acute exacerbations could reduce steroid resistance, improve emergency care, and enhance translational success across diverse populations.